Is Cidara Therapeutics, Inc. (CDTX)’s Fuel Running Low? The Stock Formed Double Bottom Chart Pattern

September 8, 2018 - By Catherine Diaz

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Logo

The chart of Cidara Therapeutics, Inc. (CDTX) shows a double bottom with $3.91 target or 8.00 % below today’s $4.25 share price. The 5 months chart pattern indicates high risk for the $117.63M company. It was reported on Sep, 8 by Finviz.com. If the $3.91 price target is reached, the company will be worth $9.41 million less. Double bottoms are rare but powerful chart patterns.

The stock increased 2.41% or $0.1 during the last trading session, reaching $4.25. About 124,269 shares traded or 13.16% up from the average. Cidara Therapeutics, Inc. (NASDAQ:CDTX) has declined 11.19% since September 8, 2017 and is downtrending. It has underperformed by 23.76% the S&P500.

Analysts await Cidara Therapeutics, Inc. (NASDAQ:CDTX) to report earnings on November, 14. They expect $-0.58 EPS, up 20.55 % or $0.15 from last year’s $-0.73 per share. After $-0.69 actual EPS reported by Cidara Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -15.94 % EPS growth.

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Ratings Coverage

Among 3 analysts covering Cidara Therapeutics (NASDAQ:CDTX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cidara Therapeutics had 3 analyst reports since May 10, 2018 according to SRatingsIntel. The firm has “Buy” rating by WBB Securities given on Wednesday, May 23. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, May 10.

Another recent and important Cidara Therapeutics, Inc. (NASDAQ:CDTX) news was published by 247Wallst.com which published an article titled: “3 Buy-Rated Biotech Stocks Under $10 With Big Upside Potential” on September 07, 2018.

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases. The company has market cap of $117.63 million. The Company’s lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious, invasive fungal infections. It currently has negative earnings. The firm also develops CD201, a novel bispecific antimicrobial immunotherapy for the treatment of multidrug-resistant gram-negative bacterial infections, including those caused by pathogens harboring the mcr-1 plasmid.

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.